results
Last reviewed 01/2018
Patients randomised to the treatment arm experienced the following benefits:
- reduced relapse rates:
- non-significant at 1 year
- 18% reduction at 2 years
- reduced disease burden as assessed by T2-weighted MRI scans
- a significant delay in six-month confirmed progression of one point on the EDSS:
- the clinical significance of this difference has been doubted